CHIN AN LIN
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
26 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 26
bookPart Qi Gong e outras práticas corporais da medicina tradicional chinesa(2019) REGUERA, Márcia Maria Ozaki; ZOO, Chen Mei; LIN, Chin AnbookPart Crônica de mentor - uma noite qualquer(2023) LIN, Chin An- The right to vaccination and the individual duty in collective health during a pandemic(2022) FRANCO, Juliana Bertoldi; GUTIERREZ, Pilar Lecussan; CABAR, Fabio Roberto; LIN, Chin An
bookPart Acupuntura e medicina baseada em evidências(2019) LIN, Chin An- Bioethical principles and values during pandemics(2020) LIN, Chin An; GRUNSPUN, Henrique; NAZARETH, Janice Caron; OLIVEIRA, Reinaldo Ayer de
bookPart História da medicina tradicional chinesa e acupuntura(2019) LIN, Chin An; HSING, Wu TubookPart Lombalgia e cervicalgia(2021) IUAMOTO, Leandro Ryuchi; SATO, Eduardo Maki; TSAI, André Wan Wen; HSING, Wu Tu; LIN, Chin An- Medical resident-centred supervision and burnout prevention(2020) NUNES, Maria do Patrocinio Tenorio; LIN, Chin An; SANTOS, Renato Antunes dos
- External validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population(2021) LAZAR NETO, Felippe; MENDES, Thiago Bosco; MATOS, Paulo Marcelo Pontes Gomes; OLIVEIRA, Julio Cesar de; FAVARATO, Maria Helena Sampaio; LIN, Chin An; MARTINS, Milton ArrudaAim: To investigate the external validity of recent antihyperglycaemic trials evaluating cardiovascular outcomes in a multimorbid population. Materials and Methods: Selection criteria of 15 randomized controlled trials from the 2020 American Diabetes Association Standard of Care statement were applied in a stepwise manner to tertiary care patients with type 2 diabetes. Primary outcomes were the number of patients eligible per individual trial and for the aggregate of trials. Secondary outcomes included patient predictors of trial eligibility. Results: Of 1059 patients, the mean (SD) age was 66 (10.74) years, the median (IQR) Charlson index was 2 (2, 3) and 458 (43%) had documented cardiovascular disease. The median (IQR) number of patients included in individual trials was 263 (174.25-308.75) and 795 (75.1%) of them were eligible for at least one trial. Among those 264 ineligible, 127 (48.1%) had an HbA1c level of 7% or less and no cardiovascular disease; 53.5% and 34.4% of the patients were eligible for two and three different classes of drugs, respectively. The strongest predictor of trial eligibility was cardiovascular disease (risk ratio 2.17, 95% CI 2.01-2.35). Conclusions: A considerable proportion of multimorbid patients would be eligible for recent antihyperglycaemic trials. This positive finding can be attributed to development guidance in diabetes trials and the different approach we took, in which we evaluated inclusion by trials as an aggregate.
bookPart A biologia do ser humano(2020) LIN, Chin An
- «
- 1 (current)
- 2
- 3
- »